ESR1 and breast cancer: In clinical practice, these criteria are replaced with equivalents on the basis of routinely assessed pathomorphological features of invasive BC, such as estrogen/progesterone receptor (ER/PR) status, HER2 status, and the Ki67 proliferation index.